Crinetics gets European approval for acromegaly drug PALSONIFY
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
April 27, 2026 5:13 PM EDTPALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union
Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly
Crinetics first regulatory approval outside of the U.S., with first launch planned for Germany and Austria
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics... More
